Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

UPDATED: Stay tuned: Biogen’s numbers are great — it’s their worrisome future that leaves analysts skittish

16 hours ago

UPDATED: Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?

17 hours ago

PACT Pharma says it's perfected the tech to select neoantigens for personalized therapy — now onto the clinic

16 hours ago

Latest

Most read

Breaking the death spiral: Hal Barron talks about transforming the moribund R&D culture at GSK in a critical year for ...

Yesterday

Why wait? Celgene restructures a big Jounce pact — zeroing in on new I/O pathway with $530M deal and bumping ICOS

9 hours ago

Proteostasis shakes up medical team; Novo funds antibiotics efforts out of Curza, Spero

15 hours ago

Little Marinus sees its shares eclipsed as the Sage rival fails to compare on PPD in PhII

18 hours ago

see latest stream

People

After a decade, ViiV CSO John Pottage says it's time to step down — and he's handing the job to longtime colleague ...

5 days ago

Biotech unicorns first to go as Neil Woodford auctions assets off suspended fund — report

5 days ago

The $1.1M goodbye: Gilead CSO John McHutchison is out as Daniel O’Day shakes up the senior team

6 days ago

Startups

Chardan's blank check company picks microbiome player BiomX for $70M reverse merger

5 days ago

Backed by some of the biggest names in biotech, Norbert Bischofberger gets his megaround for platform tech out of MIT

5 days ago

Bayer, Longwood back star researcher's deep dive into the tumor microenvironment for new I/O targets

6 days ago

Deals

Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza

20 hours ago

Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks ...

Yesterday

Celgene racks up third Otezla approval, heating up talks about who Bristol-Myers will sell to

Yesterday

IPOs

Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M

5 days ago

Following footsteps of chart-topping Chinese counterparts, Alphamab Oncology files IPO at HKEX

6 days ago

Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

H1 analysis: The high-stakes table in the biotech deals casino is paying out some record-setting winnings

Last week

The top 15 mega-deals in biopharma: AbbVie and Bristol-Myers acquisitions stir fresh debate over what's too big to ...

4 weeks ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

Last month

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 ...

2 months ago

Don't missSee all

3 years after the FDA forced Chiasma back into PhIII, they’re back with positive data — but now they have a rival

20 hours ago

Acadia is making the best of it, but their latest PhIII Nuplazid study is a bust

Yesterday

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

3 days ago

On a hot streak, Novartis execs run the odds on their two most important PhIII readouts. Which is 0.01% more likely ...

4 days ago

Peer review See all

Jul

19

Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein

Jul

12

Ex-DARPA director pursues all-in-one cancer pill as NED CEO; Karyopharm loses commercial chief ahead of drug rollout

Jul

3

Goldman Sachs' Ankang Li heads to biotech Terns as new CFO; SV recruits new partner for Dementia Discovery Fund

Jun

28

Evan Loh climbs the ladder to become CEO at Paratek Pharmaceuticals; Codiak's Doug Williams takes chairman's role at AC Immune

Jun

21

Maze interim chief Charles Homcy passes baton to Jason Coloma; William Collier tapped as CEO of Arbutus

R&D channel feed

Yesterday

Some Big Pharmas stepped up their game on data transparency — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting ...

READ MORE

Intec blitzed by PhIII flop as lead program fails to beat Merck's standard combo for Parkinson’s

Yesterday

Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use

Yesterday

latest in R&D

MyoKardia reclaims US royalty rights to heart drugs, completing conscious uncoupling from Sanofi

4 days ago

Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

4 days ago

As Acthar troubles persist, Mallinckrodt invests in RNAi and Silence Therapeutics

5 days ago

Going inside cells, Sung Joo Lee has sketched some big goals for his small — but global — team of drug hunters

6 days ago

Mallinckrodt forced to shutter ALS study testing its controversial Acthar gel

6 days ago

see latest stories

Pharma channel feed

4 days ago

Chasing Roche's aging blockbuster franchise, Amgen/Allergan roll out Avastin, Herceptin knockoffs at discount

Let the long battle for biosimilars in the cancer space begin. Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years ...

READ MORE

Takeda preps another drug auction as execs look to further trim its post-Shire buyout debt load — report

5 days ago

Gilead unleashes a $5B late-stage cash alliance with Galapagos — laying out O'Day's R&D strategy

Last week

latest in Pharma

ICER update on Duchenne drugs pushes up price estimates for Exondys 51, Emflaza ahead of July panel review

Last week

Analysis: In most of the Big Pharma world, R&D spending towers over revenue from new drugs. Guess who beat the odds

Last week

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Last week

White House changes course to kill rebate reform

Last week

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

Last week

see latest stories